IHS FormWeb
Approved Formulary
Search by name
Search by class
Browse alphabetically
Select...
NUM
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
High Alert
Restricted Medications
Renal Adjustment Policy
Therapeutic Interchange Policy
Hazard.Drug Handling(USP 800)
Hazardous Waste
Chemotherapy
IV to PO Conversion Policy
Black Box Warnings
Look-Alike/Sound-Alike
REMS
Staff Telephone Numbers
Webpage Links
Add Formweb to your mobile device
Android
iOS
Home
QuickStart
Admin
IHS FormWeb
Approved Formulary
Search by name
Additional search options
Search by class
Browse alphabetically
Select...
NUM
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
High Alert
Restricted Medications
Renal Adjustment Policy
Therapeutic Interchange Policy
Hazard.Drug Handling(USP 800)
Hazardous Waste
Chemotherapy
IV to PO Conversion Policy
Black Box Warnings
Look-Alike/Sound-Alike
REMS
Staff Telephone Numbers
Webpage Links
Search results for:
tocilizumab
tocilizumab
Restricted Medications
Non-Formulary
Brand names:
Actemra
Form
Strength
SOLUTION, INTRAVENOUS
20 mg/mL
Display
Disease-Modifying Antirheumatic Drugs
Class:
923600
Medication comments:
Restricted ICS Medications
Refrigerator item
View all
sarilumab (Kevzara)
is the alternative agent to tocilizumab (Actemra) in the setting of COVID-19.
Per policy, use of these medications is restricted as noted below:
View all
generic (Brand)
Restrictions
tocilizumab (Actemra)
Restricted from being administered at IMH,
including ICS
.
Last updated:
Feb. 9, 2024
Black Box Warnings
Serious infections risk
REMS
Actemra Injection
UpToDate
FDA DailyMed Package Insert
MedLinePlus (Patient Information)
MSDS Online
Refrigerator item